medigraphic.com
ISSN 1561-3011 (Electronic)

2014, Number 2

<< Back Next >>

Rev Cubana Invest Bioméd 2014; 33 (2)

Evaluation of the effect of Compvit-B on peripheral neuropathy in patients with mild SCA2

Velázquez-Pérez L, González GOT, Rodríguez-Labrada R, Bergado RJA, Aguilera RR, Canales ON, Coira MY, Figueredo Y, Medrano MJ, Vázquez MY, Laffita MJM

Language: Spanish
References: 28
Page: 129-139
PDF size: 78.13 Kb.


ABSTRACT

Introduction: Spinocerebellar ataxia type 2 (SCA2) is a severe neurodegenerative disease which constitutes a serious health problem in Cuba due to its high prevalence and incidence rates and the lack of curative treatments.
Objectives: Evaluate the effect and safety of the treatment with high doses of B-complex vitamins (Compvit-B) on peripheral neuropathy in patients with SCA2.
Methods: A prospective clinical intervention study was conducted of 20 patients in the mild stage of the disease undergoing a therapeutic protocol consisting in intramuscular injection of Compvit-B for 12 weeks. Patients were administered two ampoules weekly in the first 4 weeks and one from the fifth week onwards. Immediately before and after the treatment patients underwent clinical and electrophysiological examination.
Results: Upon completion of the treatment patients showed a significant increase in the amplitude of the sensitive action potentials of the median and sural nerves. In the latter case there was also a decrease in latency and an increase in conduction velocity. Motor nerve conduction parameters were not modified. Somatosensory evoked potentials of the median nerve showed a significant reduction in the latency of Erb's potential. A significant decrease was also found in the frequency of painful muscle contractures in 53% of the cases after treatment. Adverse events were not recorded during the study.
Conclusions: The study identifies a new therapeutic option for symptomatic SCA2, and provides new evidence of the pathophysiological bases and clinical management of painful muscle contractures. Broader studies should be conducted with patients and carriers of the mutation, who typically present such manifestations long before developing ataxia.


REFERENCES

  1. Pulst MS, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, Lopes-Cendes I, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nature Genet. 1996;14:269-76.

  2. Velázquez-Pérez L, Roberto Rodríguez-Labrada, Julio Cesar García-Rodríguez, Luis Enrique Almaguer-Mederos, Tania Cruz-Mariño, José Miguel Laffita-Mesa. A Comprehensive Review of Spinocerebellar Ataxia Type 2 in Cuba. Cerebellum 10:184-198, 2011.

  3. Velázquez Pérez L, Cruz GS, Santos Falcón N, Almaguer Mederos L, Escalona Batallan K, Rodriguez Labrada R, et al. Molecular epidemiology of spinocerebellar ataxias in Cuba: Insights into SCA2 founder effect in Holguin. Neurosci Lett. 2009;454(2):157-60.

  4. Klockgether T. Ataxias. In: Goetz C.G. ,editor. Textbook of clinical neurology, vol 1. Toronto: Saunder. 2007. p. 741-757.

  5. Velazquez Perez L, Sanchez Cruz G, Canales Ochoa N, Rodriguez Labrada R, Rodriguez Diaz J, Almaguer Mederos L, et al. Electrophysiological features in patients and presymptomatic relatives with spinocerebellar ataxia type 2. J Neurol Sci. 2007; 263:158-64.

  6. Velazquez-Perez L, Rodriguez-Labrada R, Canales-Ochoa N, Sanchez-Cruz G, Fernandez-Ruiz J, Montero JM, et al. Progression markers of Spinocerebellar ataxia 2. A twenty years neurophysiological follow up study. J Neurol Sci. 2010;290:22-6.

  7. Underwood BR, Rubinsztein DC. Spinocerebellar ataxias caused by polyglutamine expansions: a review of therapeutic strategies. Cerebellum. 2008;7:215-21.

  8. Konings EJ. Water soluble vitamins.Committee on Food Nutrition 2006;89(1):285-8.

  9. Ba A. Metabolic and structural role of thiamine in nervous tissues. Cell Mol Neurobiol 2008;28(7):929-31.

  10. Fernstrom J. Can nutrient supplements modify brain function? Am. J. Clin. Nutr. 71 Suppl ., 2000; 1669-73.

  11. González-Gross M, Pietrzik K. Nutrition and cognitive impairment in the elderly. Br J Nutr 2001;86(3):313-21.

  12. Mckenna MC, Rolf G, Sonnewald U, Waagepetersen HS. Molecular, Cellular and Medical Aspects, Energy Metabolism Brain. Basic Neurochemistry . 7 th Ed. ed. 2006. p. 537-51.

  13. Nigthingale LM, Paviour CD. Nutritional optic and peripheral neuropathy. Cases,J 2009;2:7762.

  14. Shy ME. Peripheral neuropathies. In: Cecil Textbook of Medicine. Goldman L, Ausiello D, editors. 23 rd ed. Philadelphia: Saunders Elsevier; 2007. p. 445.

  15. González G O.T, Canal RJ, Francis TL, Vazquez BE. Estabilidad del producto farmacéutico Compvit-B. Revista Cubana de Farmacia 2011; 45 (4);505-14.

  16. Denny-Brown D, David MD, Tyler HR. Handbook of neurological examination and case recording. Harvard: Harvard University Press, 1982.

  17. Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66(11):1717-20.

  18. Almaguer Mederos L, Santos Falcon N, Rodríguez Almira Y, Gonzalez Zaldíva Y, Martinez Gongora E, Paneque Herrera MP, et al. Estimation of age at onset in Spinocerebellar ataxia type 2 cuban patients by survival analysis. Clin genet , 2010; 78(2):169-74.

  19. Velázquez L, Medina E, Alvarez A, Santos ., García R., Oliveros N, Paneque M. Estudio clínico-electrofisiológico en 70 enfermos con Ataxia Espinocerebelosa Tipo 2. Rev Neurol 2000; 30(2):109-115

  20. Crum BA, Josephs A. Varied electrophysiologic patterns in spinocerebellar ataxia type 2. Eur J Neurol 2006, 13:194-97.

  21. Rosenfeld , J.; Ellis , A. Nutrition and Dietary Supplements in Motor Neuron Disease. Phys Med Rehabil Clin N Am. 200819(3):573-9.

  22. Roman GC. An epidemic in Cuba of optic neuropathy, sensorineural deafness, peripheral sensory neuropathy and dorsolateral myeloneuropathy. Neurol Sci 1994;127:11-28.

  23. Urban PP, Wellach I, Faiss S, Layer P, Rozenkranz T, Knop K, et al. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B 6 deficiency under duodopa therapy. Mov Disord 2010;25(11):1748-52.

  24. Schmitz-Hubsch, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu R, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology. 2010;74(8):678-84

  25. Velázquez-Pérez L, Rodríguez-Labrada R, Cruz-Rivas EM, Fernández-Ruiz J, Vaca-Palomares I, Lilia-Campins J, et al. Comprehensive study of early features in spinocerebellar ataxia 2: delineating the prodromal stage of the disease. Cerebellum. 2014;13(5):568-79.

  26. Velázquez-Pérez L, Rodríguez-Labrada R, Canales-Ochoa N, Montero JM, Sánchez-Cruz G, Aguilera-Rodríguez R, et al. Progression of early features of spinocerebellar ataxia type 2 in individuals at risk: a longitudinal study. Lancet Neurol. 2014; 13(5):482-9.

  27. Janko M, Trontelj JV, Gersak K. Fasciculations in motor neuron disease: discharge rate reflects extent and regency of collateral sprouting. J Neurol Neurosurg Psychiatry 1989;52: 1375-81.

  28. Kanai K, Kuwabara S, Arai K, Sung JY, Ogawara K and Hattori Y. Muscle cramp in Machado-Joseph disease. Altered motor axonal excitability properties and mexiletine treatment. Brain. 2003,126,965-73.




2020     |     www.medigraphic.com